Haku
Viitteet 1-7 / 7
Are products with an orphan designation for oncology indications different from products for other rare indications? : A retrospective analysis of European orphan designations granted between 2002-2012
(BioMed Central, 2017-02-16)
Background: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare ...
Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly
(Springer - Verlag, 2017-11-01)
Filgrastim is usually combined with chemotherapy to mobilize hematopoietic progenitor cells in non-Hodgkin lymphoma (NHL) patients. Limited information is available on the efficacy of a preemptive plerixafor (PLER) injection ...
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison
(American Association Of Blood Banks, 2015)
HbA1c-analytiikan tilanne Suomessa ja muualla maailmassa
(Kliinisten laboratoriotutkimusten laaduntarkkailu, 2016)
HbA1c analytiikan ja yksikköjen tilanne Suomessa syksyllä 2016
(Suomen kliinisen kemian yhdistys, 2016)
HbA1c-analytiikka ja määritysmenetelmien laatu laaduntarkkailutulosten valossa
(Suomen kliinisen kemian yhdistys r.y.,, 2018)